Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually their data release commitment last time was by the end of April 2017 per a press release in Nov 2016. The actual release was May, 1st 2017, so I guess they missed by 1 day.
If they are going to have a conference call, they need to PR that. Whether they announce the conference call and release of data, in the morning and release the data and have the CC after the bell could be. But they will have a conference call IMO.
Maybe he thinks it is better to be a day to early than a day to late. Unlike some, he has to report to the world what he owns. I bet we are going to here about all of those forgotten accounts that were bought at the bottom, as soon as positive results are released.
Coach, the warrant thing is totally bogus, first it would make zero sense to exercise warrants if you expected the stock to spike, any sane investor would wait until the stock actually went up. Second, if George Haywood was a warrant holder earlier, it would have been part of the 5% reporting requirement just like stock and options. We know that in the last 10 days he had to have acquired at least 490,000 shares of stock either through call options or common stock purchases with 470,000 shares coming from options. Think about it, who would exercise warrants and then buy call options. Pretty big bet in NTRP reporting positive results, IMO
LOl, You are kidding, right. So someone that owns warrants at $4.50+, is going to exercise them right before a major anouncenent so that he can sell the stock from the exercised warrants if the stock should make a run before the announcement, instead of using zero cash to exercise the warrants if or when the run occurs. Sounds like the same logic that Avxl has a chance to ever release results.
More fiction... "
There is no proof it is fiction, they never release real data on anything, only PR's. and AVXL never completes a trial, guess they havn't collected enough poop yet. LMAO
Yes, but you were suggesting that he exercised the warrants so he could sell them on any run up. That would be totally stupid.
Plus, warrants are not cheap, range from $4.50 to $32.
"Cashed in warrants so he can dump them on the run???? "
Please explain how that would make any sense at all? Do you need an explanation of how warrants work and what a cashless exercise is? No one would do that much less a big experienced bio investor.
LOL "Anavex has an illustrious SAB
No employees that know squat, another nothing burger from the fake CEO. Which of the SAB members collects the poop for them?
That was my point earlier, AVXL has never completed a trial. Keep it running so not to expose the failed results, hide out in Australia until the fake CEO can figure out a way to cash in.
Biggest joke here is that AVXL will ever succeed, no results, cant dose trials much less complete one, cant get peers to review junk data results.
There also were no AD patients.
Total BS, a person would have to be crazy to invest a nickel in AVXL. No results, lame CEO, not a single AD expert working for the company, cant even dose a 15 patient trail, promises the world delivers nada.
LMAO - That is a PR, from Dr Missleading, where is the peer reviewed published data on the trial. Who would invest a nickel in such BS and non credible hype.
Please link to the published results then. AVXL has none, only mumbling by their failed CEO, no credible AD experts work for the company. No readouts in 2019 as promised, cant dose a 15 patient trial. Poor excuse for a company. Park West dumping stock, AVXL is a joke.
Must have failed then, they posted no results per Clinical trials.
Anavex Life Sciences Corp.
Information provided by (Responsible Party):
Anavex Life Sciences Corp.
Study Details Tabular ViewNo Results PostedDisclaimerHow to Read a Study Record
Study Description
Go to sections
Brief Summary:
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship between dosing regimen and pharmacodynamics efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.
Of course I forgot the failed 2-73 and Donepezil trial that got all of the hipe until it crashed.
So they are now going to release data in 2020 for a trial Dr Missleading promised would be in 2019. Dont hold your breath. AVXL has not released data on any trial, because they failed them all.
Yes, I bet most of those were the Placebo patients still waiting for something to happen. Or the MCI patients that do not have AD.
This is not the AVXL pump machine, NTRP has a plan to get drug approval as soon as possible. Ntrp actually has management that have done it before. AVXL has never completed a single trial, totally clueless management.
It obviously did not fail, anyone who can understand the data has invested in it. Confirmation any day now.
But AVXL has a 98.4% chance of failure, and they have never ever completed a controlled trial.
Of course, Dr Missleading knows he needs to extend everything out for years or he is out of a job. He can't get a 15 patient trial dosed, my guess on purpose when the Rett trial turns into a nothing burger, he has to have his next Dodge ready. If they are lucky 2-73 will get fast tracked as a placebo pill in a couple of years.
Doubt PW still owns 3m shares, looks like they are selling when they can, to cut their losses. AVXL is years away from any approval, PW has figured that out.
So which is it? Maybe you are confusing the loss Park West has taken so far this year selling 500,000 shares of their biggest loser AVXL.
LOL
"no doubt put his winnings on $NTRP into $AVXL as his long term strategic investment. "
Yes, as in long term meaning "never", more likely a long term tax loss.
Less likely then some guy that does not know how to look at and understand the data, and thinks that market cap is the true test of success for a Clinical trial.
Either that or he was tricked into thinking that the FragX trial has been started.
That sounds right the amazing thing is that he does not own any warrants. Wonder if he had some and exercised them.
The 13f says 365,000 shares, plus 170,000 of which are jointly owned by his children. It gets him over 5% ownership. Guy must be crazy not to listen to the doomsday experts.
1) Includes 365,000 shares underlying call options.
2) Represents 70,000 shares, and 100,000 shares underlying call options, owned jointly by Mr. Haywood and his non-minor children
Looks like he did not get the memo, he bought 360,000 call options. Guess he does not know what he is doing according to some.
LOL - They are spending money on an incompetent, failed CEO and getting it from a sleazy finance source LPC.
"At least Anavex is spending a good deal of the money on trials, seven of them placebo controlled, triple and quadruple blinded in three different indications and four current extensions to trials requested by patients and caregivers."
But AVXL has yet to release any data on any trial muc less a controlled trial. Any data on SD is years away. Cant even dose 15 patients in a Rett trial, while promising results in 2019, how is that going. Those sham trials were meant to pump the stock and increase the profit for short sellers and more profit for LPC. Good thing they are "fast tracked" to failure so investor pain can be maximized.
I think that NTRP has conducted an effective "burnt grass" strategy to address the post results naysayers. The articles and appearances by Dr Ryan and Dr Alkon have addressed the most likely naysayer attack items. Even the SA hit job was addressed. Of course the pre-results naysayer really do not know what they are talking about and are probably just looking for attention.
"I promise you if I know about Neurotrope every does."
I would doubt that, you have been following NTRP for how long now? 6 months at the most, I bet you learned about it while following AVXL.
Dr Alkon does not want mis-interpretation of the data this time. He has learned that what is obvious to him and other AD researchers is not that obvious to a market that is use to failure. He wants to have the explanation of the data out there before results so there is no appearance of after the fact analysis, it is what he said it would be.
Yes the market has made up its mind, shorts are hoping to shake out the weak hands. Good thing the results will be released any day now and the data will speak for itself. Do you think the market's opinion will change the data?
Yes, and AVXL has a big bill to pay with their overpaid under qualified CEO. Couple that with the toxic arrangement with LPC and you have a steady drip drip drip of dilution with that stock. Also any BP deal, I believe would also include a buy out of the licencing rights from CRE.
Actually shorts went up by 200K, AVXL went up 400k in the last two weeks. You are probably right on the mm and the options balancing. NTRP is less than 7% short, while AVXL is 12%, I believe the rule of thumb is that if a stock has over 10% shorts it is a red flag.
Yes, I missed the opportunity to dump my NTRP and buy AVXL, inside info is that they got fast track approval from the FDA, and the stock will be at $10.00 before the EOD. Dont tell anybody Coach this is inside info on the QT.
Make what better? The patients this time are all on the optimal dose and are not on Namenda.
Looks to me like the next excuse for 2-73 to fail in its trials. Dr Missleading needs to have these things lined up so he can keep getting paid his huge salary and give his SAC something to write papers about.
Why would a plausible explanation be a concern. The lack of one would be a
big concern. My biggest concern for any AD trial is that a lot of the patients in the trial do not have AD. For the mild and MCI patients, studies have shown that 40%-50% even with PET scans are misdiagnosed. This trial does not have that issue because we are dealing with the worst and the worst of the worst AD patients.